AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01153-06v1
51/3/1092    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolter, N.
Right arrow Articles by Klugman, K. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolter, N.
Right arrow Articles by Klugman, K. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2007, p. 1092-1095, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01153-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

High-Level Telithromycin Resistance in a Clinical Isolate of Streptococcus pneumoniae{triangledown}

Nicole Wolter,1* Anthony M. Smith,1 Donald E. Low,2 and Keith P. Klugman1,3

Respiratory and Meningeal Pathogens Research Unit, National Institute for Communicable Diseases, Medical Research Council and University of the Witwatersrand, Johannesburg, South Africa,1 Department of Microbiology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada,2 Hubert Department of Global Health, Rollins School of Public Health, and Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, Georgia3

Received 14 September 2006/ Returned for modification 16 October 2006/ Accepted 26 December 2006

A rare clinical isolate of Streptococcus pneumoniae, highly resistant to telithromycin, contained erm(B) with a truncated leader peptide and a mutant ribosomal protein L4. By transformation of susceptible strains, this study shows that high-level telithromycin resistance is conferred by erm(B), wild type or mutant, in combination with a 69GTG71-to-TPS mutation in ribosomal protein L4.


* Corresponding author. Mailing address: Respiratory and Meningeal Pathogens Research Unit, National Institute for Communicable Diseases, Private Bag X4, Sandringham, 2131, South Africa. Phone: 27 11 555 0352. Fax: 27 11 555 0437. E-mail: nicolew{at}nicd.ac.za.

{triangledown} Published ahead of print on 8 January 2007.


Antimicrobial Agents and Chemotherapy, March 2007, p. 1092-1095, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01153-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.